Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neurofibromatosis 1 2Glioma 2Colorectal Neoplasms 2Vascular Malformations 1Skin Diseases, Vascular 1Primary Malignant Peripheral Nerve Sheath Tumors 1Oligodendroglioma 1Neurofibromatoses 1Neurofibroma 1Neurocytoma 1Neoplasms, Neuroepithelial 1NF1 1Melanoma 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Liposarcoma, Myxoid 1Liposarcoma 1KRAS Mutant Non-Small Cell Lung Cancer 1Glioblastoma 1Ganglioneuroma 1Ganglioglioma 1Central Nervous System Neoplasms 1Breast Neoplasms 1Astrocytoma 1Arteriovenous Malformations 1

Interventions

AZD 6244 9Lovastatin 5Deoxycholic Acid 4trametinib 3Lasers, Solid-State 3mirdametinib 2fludarabine 2Transcranial Direct Current Stimulation 2Sirolimus 2Polidocanol 2Magnetic Resonance Imaging 2Lasers 2Lamotrigine 2Inhalation 2Acetylcysteine 2thymoglobulin 1talimogene laherparepvec 1peginterferon alfa-2b 1gadolinium compound P760 1fludarabine phosphate 1diphenylcyclopropenone 1cabozantinib 1binimetinib 1X-Rays 1Vitamin D 1Vincristine 1Vinblastine 1Temozolomide 1Surgical Procedures, Operative 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Neurofibromatosis 1 × mirdametinib × Clear all
NCT07521657 2026-04-13

NF118

University of Alabama at Birmingham

Phase 2 Not yet recruiting
55 enrolled
CNS

Glioblastoma, Glioma, Neurofibromatosis 1

NCT02096471 2019-01-10

MEK Inhibitor

University of Alabama at Birmingham

Phase 2 Completed
19 enrolled 14 charts
CNS

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡